TNFSF10 and colitis: Moreover, adoptive transfer of TRAIL-treated T cells reduced development of bowel inflammation and colitis in a T-cell transfer colitis model, indicating that TRAIL suppressed colitogenic T-cell activation and prevented the subsequent development of autoimmune colitis.